CliffBio
small molecule

MIUDELLA

COPPER

Loss of exclusivityJanuary 2037latest FDA-listed patent expiry
CompanySEBELA WOMENS HEALTH INC

Drug detail

Brand nameMIUDELLA
Active ingredientCOPPER
StrengthN/A
Dosage formSYSTEM
RouteINTRAUTERINE
ModalitySmall molecule
FDA approvalFebruary 2025
Marketing statusRX

Listed patents

PatentExpiresType
10918516January 2037product
11207209August 2034product
10166141June 2034product
9265652April 2034use U-4155
10022264March 2034product
9180040March 2034product
10398588February 2034product
9610191February 2034use U-4155
12138199October 2033product
9089418April 2033product
10159596August 2032product
10188546August 2032product
11850181August 2032product
9427351August 2032product

Regulatory exclusivity

CodeExpires
NPFebruary 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

MIUDELLA patent cliff — loss of exclusivity January 2037 | CliffBio